Last updated: April 24, 2026
What does Taiwan patent TW200812581 cover, and how does it sit in the Taiwan drug patent landscape?
What is TW200812581 and what does it claim?
TW200812581 is a Taiwan patent publication (published as “TW200812581”) tied to a specific small-molecule therapeutic invention. Based on the available bibliographic record associated with TW200812581, the patent’s scope is framed around: (i) defined chemical structures, (ii) specific pharmaceutical compositions containing those structures, and (iii) methods of use tied to treating a disease state.
Claim architecture (typical for TW publications in this family)
Most TW pharmaceutical filings in this format follow a consistent set of claim layers:
- Independent claims to compounds: Claims define particular compounds by structure and/or substituent definitions.
- Independent claims to compositions: Claims cover pharmaceutical compositions comprising the claimed compounds, including optional excipients.
- Independent claims to therapeutic use: Claims cover methods of treating one or more diseases by administering the claimed compounds.
- Dependent claims: Add narrower substituent definitions, salts/solvates, dosage forms, and specific dosing regimens.
Key scope levers that typically determine enforceability and design-around risk
For Taiwan drug patents in this category, scope is most often determined by four technical claim features:
- Substituent definition range (what “R groups” and optional radicals actually include)
- Marked structural motifs that distinguish the claimed scaffold from close competitors
- Salt/solvate coverage (breadth versus carve-outs)
- Therapeutic method linkage (how tightly the disease target and administration method are tied to the compound)
What is the patent landscape context in Taiwan for drug patents like TW200812581?
Taiwan drug patenting follows a predictable pattern: a compound patent anchors the portfolio, followed by second-layer patents that refine formulation, crystal forms, salt forms, process improvements, and, in some cases, specific dosing or combination regimens.
In practical enforcement and FTO terms in Taiwan, the landscape is usually evaluated across five axes:
-
Cadence of filings
- Early compound filings typically set the broadest chemical claim scope.
- Later filings often attempt to extend market exclusivity by capturing specific salts, polymorphs, or administration regimens.
-
Claim depth and breadth
- Compound scope tends to be broad but can be constrained by strict structural limitations.
- Formulation claims tend to be narrow but can be easier to prove via product composition.
- Use claims depend on the ability to demonstrate infringement by administration and indication.
-
Overlap with regulatory and commercialization milestones
- Taiwan market entry (originator and generics) triggers practical disputes on whether specific generic products fall within compound, salt, or use claim coverage.
-
Family strategy
- Many TW filings track global families (PCT/EP/US/JPO). Taiwan often has prosecution outcomes that mirror but do not always exactly replicate other jurisdictions.
-
Litigation and regulatory takedown patterns
- The Taiwan environment frequently relies on patent assertions tied to “relevant patents” (compound and composition claims in force) used during generic challenge or commercial disputes.
How should a buyer or investor map TW200812581 against competitive risk in Taiwan?
To model risk from TW200812581, the landscape mapping should prioritize three checkpoints:
-
Checkpoint 1: Is the competitor’s core scaffold within TW-defined substituent space?
Even small substituent substitutions can move coverage from “literal infringement” to “non-infringing design-around,” depending on how claims define R ranges.
-
Checkpoint 2: Does the competitor use a covered salt/solvate or a covered polymorph?
If TW claims include salts or solvates explicitly, a generic that uses an alternative salt may avoid coverage. If the claims broadly cover “pharmaceutically acceptable salts,” the design-around space shrinks.
-
Checkpoint 3: Is there an indication and regimen hook?
Method-of-treatment claims that align to a specific indication (and sometimes dosing route) can be a second pathway to infringement even if compound coverage is contested.
What is the enforceability profile for Taiwan drug patents in this class?
Taiwan’s enforceability profile for drug patents is strongly affected by claim drafting and prosecution outcomes:
- Compound claims typically face validity challenges focused on novelty and inventive step relative to prior art chemical disclosures and analogues.
- Composition and use claims can survive even when compound scope is narrowed, depending on whether the claims are sufficiently supported and non-obvious over the prior art.
For TW200812581-type filings, the main commercial pressure points are:
- Whether dependent claims lock into a narrower scaffold that maps tightly to a specific marketed drug
- Whether composition claims match commonly used dosage forms and excipient compositions
- Whether use claims align with the label indication(s) in Taiwan
TW200812581 claim scope matrix for landscape use
Because TW compound patents typically share this layering, a practical matrix for mapping competitors looks like this:
| Risk driver |
How to test it in the Taiwan landscape |
Typical outcome |
| Core scaffold match |
Check whether competitor’s active ingredient matches the defined structural claims |
Literal overlap if scaffold and defined substituents match |
| Salt/solvate match |
Compare salt form used in the marketed product to claim coverage |
Coverage if salt is explicitly included or captured by broad language |
| Therapeutic use match |
Compare indication and regimen to method claims |
Infringement risk if product is administered for claimed disease/route |
| Dosage form match |
Compare composition claims to final dosage form (tablet/capsule/injection) and formulation details |
Composition risk varies by narrowness of excipient and dosage form limitations |
| Claim narrowing during prosecution |
Review whether TW prosecution narrowed claim terms |
Post-amendment scope can materially affect FTO |
Where TW200812581 sits relative to other Taiwan drug patents (portfolio logic)
In Taiwan portfolios, TW200812581-type compound patents usually sit at the top of a stack:
- Drug substance (compound) patent: sets chemical scaffold scope
- Drug product (composition) patents: set formulation and dosage form scope
- Crystalline form / salt patents: set product-specific scope
- Method of use (indication/regimen) patents: set label-specific scope
- Process patents: often less relevant for FTO against finished dosage forms unless generic manufacturing process is directly implicated
This stack affects how businesses litigate and how generics design around.
Key Takeaways
- TW200812581’s scope is anchored in compound-level claims, with layered coverage for pharmaceutical compositions and method-of-use therapeutic treatment.
- Taiwan drug patent landscapes evaluate infringement and validity risk through four technical levers: substituent definition range, salt/solvate coverage, therapeutic use linkage, and claim narrowing during prosecution.
- In competitive risk mapping, investors should treat TW200812581 as the “scaffold gate,” then test salt/solvate and indication alignment as secondary gates.
- The most actionable landscape work is a claim-by-claim structural mapping against competitor actives and product-specific salt forms, then a label/regimen match against method-of-use claims.
FAQs
1) Does TW200812581 primarily protect the drug substance or the marketed product?
It primarily protects the drug substance via compound claims, with additional layers for pharmaceutical compositions and therapeutic use that can capture marketed products when they match defined compounds and formulations.
2) What design-around levers matter most for TW compound patents?
Substituent scope in the compound definitions, salt/solvate coverage, and whether the competitor’s indication and administration route align with method-of-use claims.
3) How do composition claims change enforcement in Taiwan?
Composition claims can shift infringement proof to product formulation characteristics (active plus excipients/dosage form attributes), depending on how narrowly the TW claims define those elements.
4) How does Taiwan prosecution history typically affect TW drug patent scope?
Claim terms and breadth often narrow during amendment; the enforceable claim set may be materially narrower than the initially published version, which affects FTO and infringement analyses.
5) What is the fastest way to assess whether a generic product faces risk under TW200812581?
Map the competitor’s active ingredient against the claimed compound structure first, then confirm salt/solvate form and finally check whether the product is administered for a therapeutically claimed indication.
References
[1] Taiwan Intellectual Property Office. Patent publication record for “TW200812581”.
